These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 7647001)

  • 1. Expression of erythroid-specific genes in acute megakaryoblastic leukaemia and transient myeloproliferative disorder in Down's syndrome.
    Ito E; Kasai M; Hayashi Y; Toki T; Arai K; Yokoyama S; Kato K; Tachibana N; Yamamoto M; Yokoyama M
    Br J Haematol; 1995 Jul; 90(3):607-14. PubMed ID: 7647001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of erythroid-specific genes in megakaryoblastic disorders.
    Ito E; Kasai M; Toki T; Arai K; Yokoyama M
    Leuk Lymphoma; 1996 Nov; 23(5-6):545-50. PubMed ID: 9031085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrastructural and ultracytochemical differences between transient myeloproliferative disorder and megakaryoblastic leukaemia in Down's syndrome.
    Eguchi M; Sakaibara H; Suda J; Ozawa T; Hayashi Y; Sato T; Kojima S; Furukawa T
    Br J Haematol; 1989 Nov; 73(3):315-22. PubMed ID: 2532535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome.
    Xu G; Nagano M; Kanezaki R; Toki T; Hayashi Y; Taketani T; Taki T; Mitui T; Koike K; Kato K; Imaizumi M; Sekine I; Ikeda Y; Hanada R; Sako M; Kudo K; Kojima S; Ohneda O; Yamamoto M; Ito E
    Blood; 2003 Oct; 102(8):2960-8. PubMed ID: 12816863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
    Shimada A; Xu G; Toki T; Kimura H; Hayashi Y; Ito E
    Blood; 2004 Jan; 103(1):366. PubMed ID: 14684662
    [No Abstract]   [Full Text] [Related]  

  • 7. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
    Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
    Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.
    Boztug H; Schumich A; Pötschger U; Mühlegger N; Kolenova A; Reinhardt K; Dworzak M
    Cytometry B Clin Cytom; 2013; 84(6):370-8. PubMed ID: 23450818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.
    Groet J; McElwaine S; Spinelli M; Rinaldi A; Burtscher I; Mulligan C; Mensah A; Cavani S; Dagna-Bricarelli F; Basso G; Cotter FE; Nizetic D
    Lancet; 2003 May; 361(9369):1617-20. PubMed ID: 12747884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant progenitors common to megakaryocytic and myeloid cells in a Down's infant with transient abnormal myelopoiesis.
    Sato A; Imaizumi M; Noro T; Ichinohasama R; Saito T; Yoshinari M; Suwabe N; Suzuki H; Koizumi Y; Cui Y
    Leuk Res; 1995 Nov; 19(11):811-5. PubMed ID: 8551797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient myeloproliferative disorder in Down's syndrome: three cases with megakaryocytic markers.
    Sartori PC; Darbyshire PJ
    Pediatr Hematol Oncol; 1991; 8(2):139-45. PubMed ID: 1830754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
    McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
    Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct clones are associated with the development of transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome.
    Kanegane H; Watanabe S; Nomura K; Xu G; Ito E; Miyawaki T
    Int J Hematol; 2007 Oct; 86(3):250-2. PubMed ID: 17988992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
    Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
    Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
    Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
    Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
    Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.